Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 79-85

  Mackowick, Kristen M ^a   Barr, Mera S ^a   Wing, Victoria C ^a   Rabin, Rachel A ^a   Ouellet Plamondon, Clairelaine ^a   George, Tony P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cognition; Endophenotype; Nicotine; Nicotinic acetylcholine receptors; Schizophrenia; Tobacco

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ATTENTION; CHOLINERGIC TRANSMISSION; COGNITION; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFECT; ENDOPHENOTYPE; HUMAN; NEUROMODULATION; NEUROPSYCHOLOGY; NICOTINE REPLACEMENT THERAPY; PROTEIN FUNCTION; REACTION TIME; REVIEW; SCHIZOPHRENIA; SENSORY GATING; TASK PERFORMANCE; TOBACCO DEPENDENCE; WORKING MEMORY; ANIMAL; COGNITION DISORDERS; COMPLICATION; METABOLISM; TOBACCO USE DISORDER;

ANIMALS; COGNITION DISORDERS; ENDOPHENOTYPES; HUMANS; NICOTINE; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; TOBACCO USE DISORDER;

EID: 84899642435     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.07.010     Document Type: Review

References (92)

1. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982, 17:639-654.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993, 150:1856-1861.
3. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998, 24:189-202.
4. AhnAllen C.G., Nestor P.G., Shenton M.E., McCarley R.W., Niznikiewicz M.A. Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia. Schizophr Res 2008, 100:261-269.
5. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995, 56:395-401.
6. Avila M.T., Sherr J.D., Hong E., Myers C.S., Thaker G.K. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003, 28:2184-2191.
7. Barr R.S., Culhane M.A., Jubelt L.E., Mufti R.S., Dyer M.A., Weiss A.P., et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008, 33:480-490.
8. Barr M.S., Farzan F., Tran L.C., Chen R., Fitzgerald P.B., Daskalakis Z.J. Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophr Res 2010, 121:146-152.
9. Barr M.S., Zomorrodi R., Rajji T.K., Daskalakis Z.J. Theta-gamma coupling deficits in patients with schizophrenia. Paper presented at the Canadian College of Neuropsychopharmacology, Toronto, Ontario, Canada 2013.
10. Barr M.S., Zomorrodi R., Wing V.C., Mackowick K.M., Daskalakis Z.J., George T.P. Deficits in theta-gamma coupling in nicotine dependent patients with schizophrenia. Paper presented at the 35th international symposium of the Groupe de Recherche sur le Systeme Nerveux Central (GRSNC). Montreal, Quebec, Canada 2013.
11. Basar-Eroglu C., Brand A., Hildebrandt H., Karolina Kedzior K., Mathes B., Schmedit C. Working memory related gamma oscillations in schizophrenia patients. Int J Psychophysiol 2007, 64:39-45.
12. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001, 156:234-258.
13. 3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997, 282:7-13.
14. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000, 23:351-364.
15. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006, 63:907-915.
16. Buchanan R.W., Conley R.R., Dickinson D., Ball M.P., Feldman S., Gold J.M., et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008, 165:82-89.
17. Chambers R.A. A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia. J Dual Diagn 2009, 5:139-148.
18. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001, 50:71-83.
19. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005, 48:3474-3477.
20. Coyle J., Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001, 49:289-299.
21. Dani J.A., Jenson D., Broussard J.I., DeBiasi M. Neurophysiology of nicotine addiction. J Addict Res Ther 2011, 20:001.
22. de la Salle S., Smith D., Choueiry J., Impey D., Phillippe T., Dort H., et al. Effects of COMT genotype on sensory gating and its modulation by nicotine: differences in low and high P50 suppressors. Neuroscience 2013, 241:147-156.
23. Depatie L., O'Driscoll G.A., Holahan A.L., Atkinson V., Thavundayil J.X., Kin N.N., et al. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002, 27:1056-1070.
24. D'Souza D.C., Esterlis I., Carbuto M., Krasenics M., Seibyl J., Bois F., et al. Lower β2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry 2012, 169:326-334.
25. Esterlis I., Cosgrove K.P., Batis J.C., Bois F., Stiklus S.M., Perkins E., et al. Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med 2010, 51:1226-1233.
26. Evins A.E., Deckersbach T., Cather C., Freudenreich O., Culhane M.A., Henderson D.C., et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 2005, 66:1184-1190.
27. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995, 38:22-33.
28. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997, 94:587-592.
29. Fung Y.K., Schmid M.J., Anderson T.M., Lau Y.S. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem Behav 1996, 53:635-640.
30. Gentry C.L., Lukas R.J. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord 2002, 1:359-385.
31. George T.P. Neurobiological links between nicotine addiction and schizophrenia. J Dual Diagn 2007, 3:27-42.
32. George T.P., O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004, 25:42-48.
33. George T.P., Verrico C.D., Roth R.H. Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress. Brain Res 1998, 801:36-49.
34. George T.P., Verrico C.D., Picciotto M.R., Roth R.H. Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther 2000, 295:58-66.
35. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26:75-85.
36. George T.P., Termine A., Sacco K.A., Allen T.M., Reutenauer E., Vessicchio J.C., et al. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr Res 2006, 87:307-315.
37. Goldman-Rakic P.S. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999, 46:650-661.
38. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
39. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003, 160:636-645.
40. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004, 56:301-307.
41. Grillon C., Ameli R., Charney D.S., Krystal J., Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 1992, 32:939-943.
42. Harris J.G., Kongs S., Allensworth D., Martin L., Tregellas J., Sullivan B., et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004, 29:1378-1385.
43. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
44. Hildebrand B.E., Nomikos G.G., Hertel P., Schilstrom B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998, 779:214-225.
45. Hildebrand B.E., Panagis G., Svensson T.H., Nomikos G.G. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 1999, 21:560-574.
46. Hong L.E., Thaker G.K., McMahon R.P., Summerfelt A., Rachbeisel J., Fuller R.L., et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011, 68:1195-1206.
47. Jacobsen L.K., D'Souza D.C., Mencl W.E., Pugh K.R., Skudlarski P., Krystal J.H. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 2004, 55:850-858.
48. Judd L.L., McAdams L., Budnick B., Braff D.L. Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992, 149:488-493.
49. Kalman D., Morissette S.B., George T.P. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005, 14:106-123.
50. Keefe R.S., Eesley C.E., Poe M.P. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 2005, 57:688-691.
51. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985, 142:1259-1264.
52. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997, 11:123-131.
53. Knott V., Fisher D., Miller A. Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors. Neuroscience 2010, 170:816-826.
54. Knott V., de la Salle S., Smith D., Phillipe T., Dort H., Choueiry J., et al. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors. J Psychopharmacol 2013, [in press]. 10.1177/0269881113490449.
55. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. JAMA 2000, 284:2606-2610.
56. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., et al. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996, 22:431-445.
57. Leonard S., Breese C., Adams C., Benhammou K., Gault J., Stevens K., et al. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol 2000, 393:237-242.
58. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15:429-436.
59. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seoane F., Beaver J.S., et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013, 38:968-975.
60. Mansvelder H.D., McGehee D.S. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002, 53:606-617.
61. Martin T.J., Suchocki J., May E.L., Martin B.R. Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine. J Pharmacol Exp Ther 1990, 254:45-51.
62. Martin-Ruiz C., Lee M., Perry R.H. What is the nature of mecamylamine's antagonism of the central effects of nicotine?. Biochem Pharmacol 1989, 38:3391-3397.
63. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006, 70:801-805.
64. Mokdad A.H., Marks J.S., Stroup D.F., Gerberding J.L. Actual causes of death in the United States, 2000. JAMA 2004, 291:1238-1245.
65. Morisano D., Wing V.C., Sacco K.A., Arenovich T., George T.P. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. Am J Addict 2013, 22:46-53.
66. Olincy A., Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the a7 nicotinic receptor. Handb Exp Pharmacol 2012, 10.1007/978-3-642-25758-2_8.
67. Olincy A., Ross R.G., Young D.A., Roath M., Freedman R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 1998, 18:175-185.
68. Olincy A., Johnson L.L., Ross R.G. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 2003, 117:223-236.
69. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006, 166:1571-1577.
70. Pachas G.N., Cather C., Pratt S.A., Hoeppner B., Nino J., Carlini S.V., et al. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. J Dual Diagn 2012, 8:117-125.
71. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008, 158:226-247.
72. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 2003, 24:493-499.
73. Pidoplichko V.I., DeBiasi M., Williams J.T., Dani J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997, 390:401-404.
74. Sacco K.A., Bannon K.L., George T.P. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 2004, 18:457-474.
75. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005, 62:649-659.
76. Sacco K.A., Termine A., Dudas M.M., Seyal A.A., Allen T.M., Vessicchio J.C., et al. Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Schizophr Res 2006, 85:213-221.
77. Sacco K.A., Creeden C., Reutenauer E.L., George T.P. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophr Res 2008, 103:326-327.
78. Schubert M.H., Young K.A., Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006, 60:530-533.
79. Shim J.C., Jung D.U., Jung S.S., Seo Y.S., Cho D.M., Lee J.H., et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012, 37:660-668.
80. Slemmer J.E., Martin B.R., Damaj M.I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000, 295:321-327.
81. Smith R.C., Singh A., Infante M., Khandat A., Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002, 27:479-497.
82. Smith R.C., Warner-Cohen J., Matute M., Butler E., Kelly E., Vaidhyanathaswamy S., et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006, 31:637-643.
83. Smith R.C., Lindenmayer J.P., Davis J.M., Cornwell J., Noth K., Gupta S., et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009, 110:149-155.
84. Tidey J.W., Rohsenow D.J., Kaplan G.B., Swift R.M. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend 2005, 80:259-265.
85. Tonstad S., Tonnesen P., Hajek P., Williams K., Billing C., Reeves K. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296:64-71.
86. Vezina P., Blanc G., Glowinski J., Tassin J.P. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J Pharmacol Exp Ther 1992, 261:484-490.
87. Williams J.M., Anthenelli R.M., Morris C.D., Treadow J., Thompson J.R., Yunis C., et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012, 73:654-660.
88. Wing V.C., Sacco K.A., George T.P. Spatial working memory impairments induced by cigarette smoking abstinence are correlated with plasma nicotine levels in schizophrenia. Schizophr Res 2011, 128:171-172.
89. Wing V.C., Bacher I., Sacco K.A., George T.P. Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Res 2011, 188:320-326.
90. Wing V.C., Wass C.E., Soh D.W., George T.P. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci 2012, 1248:89-106.
91. Winterer G. Why do patients with schizophrenia smoke?. Curr Opin Psychiatry 2010, 23:112-119.
92. Woznica A.A., Sacco K.A., George T.P. Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res 2009, 112:86-90.